CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 467 enrolled / 467 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06467370
NCT06467370N/ACompletedHigh Momentum (19.5/mo)Completion was 15mo ago

CONFIDENCE: A PROSPECTIVE OBSERVATIONAL STUDY WITH ACUTE TREATMENT OF RIMEGEPANT ODT ON CONSISTENCY, SATISFACTION AND TOLERABILITY OF TREATMENT IN THE REAL WORLD

Pfizer·observational·Posted Jun 21, 2024·Updated Jun 30, 2026

In Brief

An observational study for Migraine. Completed, enrolled 467 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely monoclonal antibodies targeting CGRP and onabotulinumtoxinA

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States

Timeline

N/ACompletedFinished
20252026
First PostedJun 21, 2024
Enrollment StartJul 2, 2024
Primary CompletionMar 11, 2025
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 2.0 years ago